A detailed history of Royal Bank Of Canada transactions in Cure Vac N.V. stock. As of the latest transaction made, Royal Bank Of Canada holds 14,461 shares of CVAC stock, worth $41,503. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,461
Previous 11,968 20.83%
Holding current value
$41,503
Previous $40,000 5.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.74 - $3.79 $6,830 - $9,448
2,493 Added 20.83%
14,461 $42,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $4.99 $9,320 - $20,134
4,035 Added 50.86%
11,968 $40,000
Q1 2024

Nov 05, 2024

SELL
$2.94 - $4.34 $11,862 - $17,511
-4,035 Reduced 33.71%
7,933 $24,000
Q1 2024

May 15, 2024

BUY
$2.94 - $4.34 $2,543 - $3,754
865 Added 12.24%
7,933 $24,000
Q4 2023

Feb 14, 2024

SELL
$3.96 - $6.41 $39,603 - $64,106
-10,001 Reduced 58.59%
7,068 $29,000
Q3 2023

Nov 14, 2023

BUY
$6.5 - $10.77 $12,896 - $21,367
1,984 Added 13.15%
17,069 $116,000
Q2 2023

Aug 14, 2023

BUY
$6.69 - $12.25 $13,660 - $25,014
2,042 Added 15.66%
15,085 $157,000
Q1 2023

May 15, 2023

BUY
$6.38 - $12.5 $59,334 - $116,250
9,300 Added 248.46%
13,043 $90,000
Q4 2022

Feb 14, 2023

SELL
$5.75 - $8.5 $42,412 - $62,696
-7,376 Reduced 66.34%
3,743 $22,000
Q3 2022

Nov 14, 2022

BUY
$7.48 - $15.24 $9,574 - $19,507
1,280 Added 13.01%
11,119 $87,000
Q2 2022

Aug 15, 2022

SELL
$13.18 - $19.41 $33,740 - $49,689
-2,560 Reduced 20.65%
9,839 $133,000
Q1 2022

May 16, 2022

SELL
$14.73 - $35.25 $12,049 - $28,834
-818 Reduced 6.19%
12,399 $243,000
Q4 2021

Feb 14, 2022

BUY
$33.72 - $48.22 $237,422 - $339,517
7,041 Added 114.01%
13,217 $453,000
Q3 2021

Nov 15, 2021

BUY
$49.26 - $74.5 $214,182 - $323,926
4,348 Added 237.86%
6,176 $339,000
Q2 2021

Aug 16, 2021

BUY
$56.91 - $127.53 $104,031 - $233,124
1,828 New
1,828 $134,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $538M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.